Oncology Podcast

El potencial de los inhibidores de PARP en el cáncer de próstata: Lo que las enfermeras deben saber

En el segundo episodio de esta serie de podcasts, Pablo Peinado y la Dra. Elena Castro analizan los inhibidores de PARP, cómo funcionan, revisan datos clave de ensayos, cómo seleccionar PARPi y dónde encajan en la secuencia general de tratamiento.

Pablo Peinado

Pablo Peinado
Dr Elena Castro

Dr Elena Castro
Publication Date

Jan 2022

download Downloadable resources

Listen and follow our podcasts on:

AstraZeneca

spotify Listen on Spotify Podcasts
apple Listen on Apple Podcasts

Escuche el Episodio 2 - El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber

 

El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber (Episodio 2 de 3)

En este episodio, Pablo Peinado y la Dra. Elena Castro analizan los inhibidores de PARP, cómo funcionan, revisan los datos clave de los ensayos, cómo seleccionar los PARPi para sus pacientes con cáncer de próstata y dónde encajan en la secuencia general del tratamiento, además de brindar información sobre la comunicación con los pacientes, los PARPi que actualmente se encuentran en una etapa avanzada de desarrollo y el posible uso futuro de PARPi en combinación con inmunoterapias o inhibidores de la vía del receptor de andrógenos.

En el Episodio 1, Pruebas genéticas e inhibidores de PARP en el cáncer de próstata, Joanne Chien y el Dr. Alexander Wyatt analizan las alteraciones genéticas en el cáncer de próstata y por qué debemos considerar las pruebas genéticas al pensar en opciones de tratamiento como los inhibidores de PARP (PARPi). La discusión cubre por qué se deben realizar pruebas genéticas, quién debe someterse a las pruebas, cómo realizar las pruebas y qué significa esto en relación con el tratamiento con inhibidores de PARP.

El Dr. Alexander Wyatt explica la diferencia entre las mutaciones somáticas y de la línea germinal y Joanne Chien analiza el papel de la enfermera durante las discusiones de asesoramiento genético y cómo este papel puede evolucionar en el futuro. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y si es probable que el resultado de estos ensayos afecte a la necesidad de realizar pruebas genéticas.

En el tercer y último episodio, Inhibidores de PARP en el cáncer de próstata: manejo de eventos adversos y la importancia de la comunicación con los pacientes, el Dr. Jason Alcorn y la Dra. Alicia Morgans analizan los eventos adversos asociados con los inhibidores de PARP y el manejo de los mismos, en particular trombocitopenia, efectos gastrointestinales y fatiga. Jason proporciona información sobre cómo las enfermeras apoyan y se comunican con los pacientes, la importancia de la notificación temprana de los efectos secundarios y cómo manejarlos. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y lo que estos ensayos pueden significar para los pacientes.

 

Este podcast GU NURSES CONNECT también está disponible en

Castos, Spotify, Podcasts de Apple y Podcasts de Google

Pablo Peinado is a Senior Research Nurse Coordinator at Hospital Universitario Virgen de la Victoria in Malaga, Spain.  Pablo gained his Nursing Degree at the University of Valencia in 2014 and moved to the UK where he worked as a surgical nurse for two years.  In 2016 he received his Clinical Trials master’s degree and started to work as a Haematology Research Nurse at Churchill Hospital, Oxford where he was in charge of conducting different clinical trials for haematology patients. Pablo moved back to Spain in 2017 to be part of a new GU tumour unit under Dr David Olmos at Hospital Virgen de la Victoria, Malaga and worked as an Oncology Research Nurse with GU patients diagnosed with prostate, bladder and kidney cancer, coordinating early and late phase clinical trials.  He has recently been promoted to lead a new Clinical Research Unit and is in charge of coordinating a unit where the objectives are to treat patients with the most advanced medications and provide a personalised approach to their disease so that they can participate more actively during their treatment, learning about their disease and understanding the process of their treatment.

Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain.  She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain.  After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK.   Later, she joined the Spanish National Cancer Research Center as a clinician-scientist.  Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.   

Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix. 
The potential of PARP inhibitors in prostate cancer: What nurses need to know

Episode

2

of 3

episodes
GU NURSES CONNECT
The potential of PARP inhibitors in prostate cancer: What nurses need to know

Episode 2

Experts
Dr Elena Castro, Pablo Peinado
Endorsed By
The potential of PARP inhibitors in prostate cancer: What nurses need to know
  • download Downloadable
    Resouces
  • clock 25 MIN
  • calendar Jan 2022
  • EACCME Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from AstraZeneca

Listen and follow our podcasts on:

AstraZeneca

spotify Listen on Spotify Podcasts

Escuche el Episodio 2 - El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber

 

El potencial de los inhibidores de PARP en el cáncer de próstata: lo que las enfermeras deben saber (Episodio 2 de 3)

En este episodio, Pablo Peinado y la Dra. Elena Castro analizan los inhibidores de PARP, cómo funcionan, revisan los datos clave de los ensayos, cómo seleccionar los PARPi para sus pacientes con cáncer de próstata y dónde encajan en la secuencia general del tratamiento, además de brindar información sobre la comunicación con los pacientes, los PARPi que actualmente se encuentran en una etapa avanzada de desarrollo y el posible uso futuro de PARPi en combinación con inmunoterapias o inhibidores de la vía del receptor de andrógenos.

En el Episodio 1, Pruebas genéticas e inhibidores de PARP en el cáncer de próstata, Joanne Chien y el Dr. Alexander Wyatt analizan las alteraciones genéticas en el cáncer de próstata y por qué debemos considerar las pruebas genéticas al pensar en opciones de tratamiento como los inhibidores de PARP (PARPi). La discusión cubre por qué se deben realizar pruebas genéticas, quién debe someterse a las pruebas, cómo realizar las pruebas y qué significa esto en relación con el tratamiento con inhibidores de PARP.

El Dr. Alexander Wyatt explica la diferencia entre las mutaciones somáticas y de la línea germinal y Joanne Chien analiza el papel de la enfermera durante las discusiones de asesoramiento genético y cómo este papel puede evolucionar en el futuro. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y si es probable que el resultado de estos ensayos afecte a la necesidad de realizar pruebas genéticas.

En el tercer y último episodio, Inhibidores de PARP en el cáncer de próstata: manejo de eventos adversos y la importancia de la comunicación con los pacientes, el Dr. Jason Alcorn y la Dra. Alicia Morgans analizan los eventos adversos asociados con los inhibidores de PARP y el manejo de los mismos, en particular trombocitopenia, efectos gastrointestinales y fatiga. Jason proporciona información sobre cómo las enfermeras apoyan y se comunican con los pacientes, la importancia de la notificación temprana de los efectos secundarios y cómo manejarlos. Finalmente, también se consideran los ensayos en curso de inhibidores de PARP en combinación con otros tratamientos para el cáncer de próstata y lo que estos ensayos pueden significar para los pacientes.

 

Este podcast GU NURSES CONNECT también está disponible en

Castos, Spotify, Podcasts de Apple y Podcasts de Google

Pablo Peinado is a Senior Research Nurse Coordinator at Hospital Universitario Virgen de la Victoria in Malaga, Spain.  Pablo gained his Nursing Degree at the University of Valencia in 2014 and moved to the UK where he worked as a surgical nurse for two years.  In 2016 he received his Clinical Trials master’s degree and started to work as a Haematology Research Nurse at Churchill Hospital, Oxford where he was in charge of conducting different clinical trials for haematology patients. Pablo moved back to Spain in 2017 to be part of a new GU tumour unit under Dr David Olmos at Hospital Virgen de la Victoria, Malaga and worked as an Oncology Research Nurse with GU patients diagnosed with prostate, bladder and kidney cancer, coordinating early and late phase clinical trials.  He has recently been promoted to lead a new Clinical Research Unit and is in charge of coordinating a unit where the objectives are to treat patients with the most advanced medications and provide a personalised approach to their disease so that they can participate more actively during their treatment, learning about their disease and understanding the process of their treatment.

Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain.  She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain.  After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK.   Later, she joined the Spanish National Cancer Research Center as a clinician-scientist.  Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.   

Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix. 
The potential of PARP inhibitors in prostate cancer: What nurses need to know

Episode

2

of 3

episodes
GU NURSES CONNECT
The potential of PARP inhibitors in prostate cancer: What nurses need to know

Episode 2

Experts
Dr Elena Castro, Pablo Peinado
Endorsed By
The potential of PARP inhibitors in prostate cancer: What nurses need to know
  • clock MIN
  • calendar Jan 2022
  • EACCME Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Programme summary
  • clock Duration 25 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
Urobel VZW | ASBL
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
Urobel VZW | ASBL
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
COR2ED Non-accredited Independent Medical Education
The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Dr Sara Lonardi
  • clock 5 MIN
  • calendar Jun 2025
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Explore all programmes